Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 NASH and the Gut Microbiome: Implications for New Therapies.

Literature DB >> 35355843

NASH and the Gut Microbiome: Implications for New Therapies.

Cynthia J Tsay¹, Joseph K Lim².

Abstract

Content available: Author Audio Recording.

Entities: Chemical

Year: 2022 PMID： 35355843 PMCID： PMC8958237 DOI： 10.1002/cld.1170

Source DB: PubMed Journal: Clin Liver Dis (Hoboken) ISSN： 2046-2484

Keyword Cloud
References

23 in total

1. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.

Authors: Anne Vrieze; Els Van Nood; Frits Holleman; Jarkko Salojärvi; Ruud S Kootte; Joep F W M Bartelsman; Geesje M Dallinga-Thie; Mariette T Ackermans; Mireille J Serlie; Raish Oozeer; Muriel Derrien; Anne Druesne; Johan E T Van Hylckama Vlieg; Vincent W Bloks; Albert K Groen; Hans G H J Heilig; Erwin G Zoetendal; Erik S Stroes; Willem M de Vos; Joost B L Hoekstra; Max Nieuwdorp
Journal: Gastroenterology Date: 2012-06-20 Impact factor: 22.682

2. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.

Authors: Adnan Said; Ahmed Akhter
Journal: Ann Hepatol Date: 2017 Jul-Aug Impact factor: 2.400

Review 3. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease.

Authors: Giovanni Tarantino; Carmine Finelli
Journal: Future Microbiol Date: 2015 Impact factor: 3.165

4. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.

Authors: Fatemeh Mofidi; Hossein Poustchi; Zahra Yari; Babak Nourinayyer; Shahin Merat; Maryam Sharafkhah; Reza Malekzadeh; Azita Hekmatdoost
Journal: Br J Nutr Date: 2017-03-27 Impact factor: 3.718

Review 5. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

Authors: Siddharth Singh; Rohan Khera; Alina M Allen; M Hassan Murad; Rohit Loomba
Journal: Hepatology Date: 2015-10-01 Impact factor: 17.425

6. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.

Authors: Lixin Zhu; Susan S Baker; Chelsea Gill; Wensheng Liu; Razan Alkhouri; Robert D Baker; Steven R Gill
Journal: Hepatology Date: 2013-01-08 Impact factor: 17.425

NASH and the Gut Microbiome: Implications for New Therapies.

1. Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome.

2. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.

Review 3. Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease.

4. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial.

Review 5. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis.

6. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: a connection between endogenous alcohol and NASH.

Review 7. Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy.

8. The Intestinal Microbiome, Plasma Metabolome, and Liver Transcriptome: A Conspiracy Driving Hepatic Steatosis.

9. Intestinal microbiota in patients with nonalcoholic fatty liver disease.

Review 10. The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies.